Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS

Nat Rev Neurol. 2013 Mar;9(3):125-6. doi: 10.1038/nrneurol.2013.2. Epub 2013 Jan 29.

Abstract

Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD / immunology
  • Antigens, Neoplasm / immunology
  • CD52 Antigen
  • Clinical Trials, Phase III as Topic
  • Glycoproteins / immunology
  • Humans
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab